Clinical Trials Logo

Head Trauma clinical trials

View clinical trials related to Head Trauma.

Filter by:

NCT ID: NCT00847977 Terminated - Head Trauma Clinical Trials

Interest of Using Balanced Fluid for Infusion at the Early Phase of an Acute Cranial Trauma for Limiting Hyperchloremic Acidosis

IsoTC
Start date: October 2008
Phase: Phase 3
Study type: Interventional

isotonic NaCl serum is the first intent solution for infusion during the initial phase of reanimation for an acute cranial traumatism. However, its use can trigger an hyperchloremic metabolic acidosis, what could be deleterious for the future of this patient. Isofundine present all charateristics to be use in this indication: pharmacokinetic and pharmacodynamic similar to the physiologic serum, iso-osmolarity to plasma, no glucose provision and no interaction with hemostasis.

NCT ID: NCT00622778 Completed - Head Trauma Clinical Trials

Immunemodulation in Patients With Minor Head Injury

MHI
Start date: October 2007
Phase: N/A
Study type: Observational

The purpose of this study is to try to prove the worth of the two (2) Serum Proteins S-100 Beta and NSE in combination with a diagnostic algorithm to help to establish diagnosis in patients with minor head injury.

NCT ID: NCT00196131 Active, not recruiting - Clinical trials for Subarachnoid Hemorrhage

Problems With Morphine Use in Patients With a Severe Brain Injury

Start date: January 2005
Phase: Phase 1/Phase 2
Study type: Interventional

Hypothesis: During severe brain trauma (injury, surgery) the ensuing inflammatory response in the central nervous system (CNS) results in a decrease in the expression of the transporter protein p-glycoprotein (PGP) in the blood brain barrier. This loss results in the penetration into the brain of certain drugs that are normally excluded by the transporter protein. In this study the working hypothesis is that the agitation observed in patients with CNS trauma treated with morphine is related to the inflammation evoked loss of PGP in the blood brain barrier and the accumulation of the morphine metabolite 3-morphine glucuronide.